<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03984708</url>
  </required_header>
  <id_info>
    <org_study_id>DR180135</org_study_id>
    <secondary_id>2019-A00649-48</secondary_id>
    <nct_id>NCT03984708</nct_id>
  </id_info>
  <brief_title>New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways.</brief_title>
  <acronym>METABOCALS</acronym>
  <official_title>New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects central and&#xD;
      peripheral motor neurons. None of the clinical trials conducted have been clearly successful&#xD;
      and the disease remains incurable, putting patients' vital prognosis at risk in the medium&#xD;
      term. An alteration of the basal metabolism leading to hypermetabolism has been described in&#xD;
      several articles in the literature. The causes of this hypermetabolism and the precise&#xD;
      exploration of the metabolic pathways involved are still poorly understood. The fibroblasts&#xD;
      of ALS patients may be the site of some metabolic disturbances in this disease with a&#xD;
      hypothetical specific basal metabolic profile. These cells are adapted to different metabolic&#xD;
      explorations such as omnic approaches. Superficial skin biopsy followed by fibroblast culture&#xD;
      can provide a considerable biobank. This cellular richness will allow us, in ALS patients and&#xD;
      their controls, to perform metabolomic and lipidomic approaches, as well as the&#xD;
      quantification transcriptomic approach.&quot;&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects central and&#xD;
      peripheral motor neurons. None of the clinical trials conducted have been clearly successful&#xD;
      and the disease remains incurable, putting patients' vital prognosis at risk in the medium&#xD;
      term. An alteration of the basal metabolism leading to hypermetabolism has been described in&#xD;
      several articles in the literature. The causes of this hypermetabolism and the precise&#xD;
      exploration of the metabolic pathways involved are still poorly understood. The fibroblasts&#xD;
      of ALS patients may be the site of some metabolic disturbances in this disease with a&#xD;
      hypothetical specific basal metabolic profile. These cells are adapted to different metabolic&#xD;
      explorations such as omnic approaches. Superficial skin biopsy followed by fibroblast culture&#xD;
      can provide a considerable biobank. This cellular richness will allow us, in ALS patients and&#xD;
      their controls, to perform experiments for the quantification of metabolites by metabolic and&#xD;
      lipidomic approaches, as well as the quantification of mRNAs and the rate of gene&#xD;
      transcription by a transcriptomic approach.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2020</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic signature of fibroblast : concentrations of molecules detected by mass spectrometry</measure>
    <time_frame>Baseline</time_frame>
    <description>The metabolomic profile of fibroblast represents the combination of the different molecules detected/quantified by mass spectrometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic signature of blood : concentrations of molecules detected by mass spectrometry</measure>
    <time_frame>Baseline</time_frame>
    <description>The metabolomic profile of blood represents the combination of the different molecules detected/quantified by mass spectrometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression levels of targeted molecules using transcriptomics</measure>
    <time_frame>Baseline</time_frame>
    <description>Choice of molecules based on results obtained by metabolomics approaches</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The intervention, specific to the study, is to take samples at baseline on patients with Amyotrophic Lateral Sclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The intervention, specific to the study, is to take samples at baseline on patients without neurological disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Samples</intervention_name>
    <description>Blood sample, skin biopsy</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Indirect calorimetry</intervention_name>
    <description>Measurement of energy expenditure by indirect calorimetry</description>
    <arm_group_label>Case group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electrical bioimpedance</intervention_name>
    <description>Measurement of electrical bioimpedance</description>
    <arm_group_label>Case group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Case group selection criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years and ≥ 75 years&#xD;
&#xD;
          -  ALS according to the El Escorial criteria&#xD;
&#xD;
          -  Diagnosis of ALS &lt; 6 months&#xD;
&#xD;
          -  Symptoms onset &lt; 2 years&#xD;
&#xD;
          -  Patients affiliated to social security scheme&#xD;
&#xD;
          -  Informed consent signed by the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Contraindication to biopsy&#xD;
&#xD;
          -  Contraindication to local anesthesia&#xD;
&#xD;
          -  Treatment with oral or injectable anticoagulants, antiplatelet (except aspirin)&#xD;
&#xD;
          -  Unbalanced Diabetes&#xD;
&#xD;
          -  Systemic corticosteroid treatment&#xD;
&#xD;
          -  Dermatological diseases of the fibroblast&#xD;
&#xD;
          -  Skin cancer&#xD;
&#xD;
          -  Protection measure for guardianship or curatorship&#xD;
&#xD;
        Control group selection criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years and ≥ 75 years&#xD;
&#xD;
          -  No neuronal disease&#xD;
&#xD;
          -  Patients affiliated to social security scheme&#xD;
&#xD;
          -  Informed consent signed by the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Contraindication to biopsy&#xD;
&#xD;
          -  Treatment with oral or injectable anticoagulants, antiplatelet (except aspirin)&#xD;
&#xD;
          -  Unbalanced Diabetes&#xD;
&#xD;
          -  Systemic corticosteroid treatment&#xD;
&#xD;
          -  Dermatological diseases of the fibroblast&#xD;
&#xD;
          -  Skin cancer&#xD;
&#xD;
          -  Protection measure for guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène BLASCO, MD-PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hélène BLASCO, MD-PhD</last_name>
    <phone>02.34.37.89.11</phone>
    <phone_ext>+33</phone_ext>
    <email>helene.blasco@univ-tours.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurology Department, University Hospital, Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe COURATIER, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe COURATIER, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Department, University Hospitla, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe CORCIA, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe CORCIA, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Metabolomics</keyword>
  <keyword>Transcriptomics</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Fibroblast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

